The epilepsy specialist and Cleveland Clinic’s Chief Research and Information Officer detailed the steps and teamwork required to implement a machine learning that predicts seizure outcomes in epilepsy surgery. [WATCH TIME: 4 minutes]
The professor of emergency medicine at the University of Wisconsin-Madison School of Medicine and Public Health spoke about how telemedicine in senior living communities can effectively decrease ED use by individuals with dementia.
The director of the Pediatric Stroke Program at CHOP discussed the findings of a single-center study exploring the incidence of children presenting with acute arterial ischemic stroke who may have been eligible for mechanical thrombectomy.
The investigator at the Healey & AMG Center for ALS at Massachusetts General Hospital spoke to the data backing the investigational AMX0035 in the treatment of ALS. [WATCH TIME: 3 minutes]
With the CMSC 2021 annual meeting having wrapped up, the director of the Multiple Sclerosis/MRI Research Group at the University of British Columbia offered his perspective on this year’s conference. [WATCH TIME: 1 minute]
Host Jeffrey Wilken, PhD, chats with Marijean Buhse, PhD, RN, NP-C, MSCN; Amy Sullivan, PsyD, ABPP; and John DeLuca, PhD, ABPP, FACRM, FAPA, FAPS, FNAN, about the third day of the 2024 CMSC Annual Meeting in Nashville, Tennessee.
The senior lecturer in Clinical Pharmacy at Aston University talked about issues facing the medical community in treating those with dementia who have sleep problems.
Interest in advancing research in stroke therapeutics has historically come in fits and starts. Now with intravenous tPA and thrombectomy in regular use, experts are looking to get a step ahead of the damage.
Cannabinoids are being explored in a variety of conditions, ranging from Alzheimer disease to migraine.
Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, share key takeaways for clinicians treating RRMS.
Chylinski spoke about the relationship between the increased number of arousals during sleep and the pathogenesis of Alzheimer disease.
Currently, there are no disease-modifying medications for Huntington disease and few interventions available to effectively alleviate symptoms, while the lack of indicators of pathobiological processes at the molecular level has limited the ability to prove efficacy and safety in clinical trials.
Selkoe spoke to a number of topics in the Alzheimer space, including the challenges in the field and his excitement for the future.
The director of the Sleep Disorders Center and vice-chair of the department of neurology at UCLA David Geffen School of Medicine detailed the greatest need in the management of narcolepsy
The senior VP of Global Health Economics and Outcomes Research and Epidemiology at Biohaven Pharmaceuticals discussed the findings from a poster presentation on the economic impact of migraine disability at AHS 2020.
Over a 2-year period, SRP-9003 elicited sustained protein expression in muscle tissue and stabilized North Star Assessment for Dysferlinopathies scores.
The director of the Orange County Migraine and Headache Center spoke about the adherence issues in acute migraine treatment and how the safety profile of investigational medications such as rimegepant and ubrogepant suggests they may be able to address them.
The Clinical Fellow in Neurophysiology and Epilepsy at Massachusetts General Hospital spoke about the implications of this assessment of SUDEP.
The professor of neurology at the Geisel School of Medicine at Dartmouth broke down the FDA approval of STS101, a new DHE nasal powder, and its implications for acute migraine care. [WATCH TIME: 7 minutes]
Two experts explain the impact of the drug fenfluramine’s FDA approval in the treatment of Dravet syndrome.
In recognition of World Alzheimer Day, experts in Alzheimer disease and dementia share insight from the latest Alzheimer Disease International's yearly World Alzheimer Report.
Our patients have a huge need for access to specialists, yet unfortunately, there is a huge shortage of headache specialists.
The assistant professor of neurology at Mount Sinai Health System spoke about the recent trend toward approaching migraine in a more holistic fashion, and the incorporation of nonpharmacologic options for patients with the chronic headache condition.
The director of Centers for Neuropsychology and Neuroscience Research, and Traumatic Brain Injury Research at Kessler Foundation discussed the use of cognitive rehabilitation techniques in healthy individuals.
Preliminary findings from a retrospective sample series in the Bronx, New York.
The Director of the cEEG and Epilepsy Consult Service at the Cleveland Clinic Epilepsy Center spoke about the cautious for physicians treating patients with acute symptomatic seizures.
Panelists discuss how challenges in prescribing subcutaneous infusion systems might affect patient adherence and device management, best practices for patient education, and what additional data would benefit clinicians implementing newer Parkinson disease treatments.
The director of the Jefferson Headache Center at Jefferson University Hospital discussed the need for physicians to revisit how they treat patients with chronic migraine who have developed medication overuse headache.
Two-thirds of patients with critical results were African American, demonstrating an additional need to explore associations between ethnicity and COVID-19.